EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections
- 27 April 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 24 (9), 3943-3950
- https://doi.org/10.1007/s00520-016-3231-1
Abstract
Purpose Epidermal growth factor receptor (EGFR) inhibitors are approved for use as targeted chemotherapeutic agents against multiple solid-organ malignancies. The most common side effect associated with EGFR inhibitor therapy is a papulopustular eruption, which can easily be confused with bacterial folliculitis. In this study, we examine the relative timing and location of the EGFR-induced papulopustular eruption compared to the associated bacterial superinfections. Methods In this retrospective chart review, patients enrolled in our institution’s IRB-approved prospective registry of cutaneous reactions to chemotherapy were screened for inclusion. All patients who received an EGFR inhibitor and developed either a papulopustular eruption or bacterial superinfection at some point during treatment were included. Results Of the 157 patients who met inclusion criteria, 36 (23 %) developed bacterial superinfections at some point during EGFR therapy. Papulopustular eruptions developed in a highly predictable time course, with a mean time to onset of 1.5 weeks and mean duration of 9.4 weeks. Bacterial superinfections occurred at widely variable time points during therapy with a mean time to onset of 27.7 weeks. Papulopustular eruptions much more frequently affected the face (97 %), chest (75 %), and back (61 %), while bacterial superinfections occurred more commonly on the upper extremity (64 %), lower extremity (47 %), and abdomen (39 %). Conclusions The EGFR inhibitor-induced papulopustular eruption has a stereotypical time course and occurs in a characteristic distribution affecting the central face, upper chest, and back. Bacterial superinfections more frequently affect the extremities, abdomen, and groin and may occur at any point during EGFR therapy.Funding Information
- None
This publication has 29 references indexed in Scilit:
- Epidermal EGFR Controls Cutaneous Host Defense and Prevents InflammationScience Translational Medicine, 2013
- Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitorsJournal of Cutaneous Pathology, 2013
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEuropean Journal of Cancer, 2010
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic CooperationClinical Colorectal Cancer, 2008
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Blockade of the EGF Receptor Induces a Deranged Chemokine Expression in Keratinocytes Leading to Enhanced Skin InflammationThe American Journal of Pathology, 2003
- The EGF receptor - an essential regulator of multiple epidermal functions.2000
- Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant PhenotypeScience, 1995
- Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human SkinJournal of Investigative Dermatology, 1990